Brazil Diabetes Drugs Market Analysis Report 2022 to 2030

Brazil Diabetes Drugs Market Analysis

$ 3999

The Brazil diabetes drugs market size was valued at $1.54 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $2.67 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Brazil diabetes drug market will grow because the growing aging population, as the population ages, the incidence of diabetes is expected to increase, creating a greater demand for diabetes drugs. The key market players are Ache Laboratorios Farmaceuticos (BRA), Biolab Sanus Farmaceutica (BRA), Cristália Produtos Químicos (BRA), EMS Sigma Pharma (BRA)Boehringer Ingelheim, and others.

ID: IN10BRPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Chandani Patel

Buy Now

Brazil Diabetes Drugs Market Executive Summary

The Brazil diabetes drugs market size was valued at $1.54 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $2.67 Bn in 2030. Brazil is one of the largest economies in the world and has a large population, which has significant implications for its healthcare system and healthcare expenditure. According to the World Health Organization (WHO), Brazil spent approximately 9% of its gross domestic product (GDP) on healthcare in 2017. This is higher than the average for Latin America and the Caribbean, which was approximately 6.6% of GDP in the same year.

Public spending accounts for a significant proportion of healthcare expenditure in Brazil, with the government funding around 46% of all healthcare spending in 2017. Private spending, including out-of-pocket spending by individuals and spending by private health insurance providers, accounted for the remaining 54%.

Brazil has a high prevalence of diabetes, with approximately 21 million people between the ages of 20 and 79 affected, according to the International Diabetes Federation's Diabetes Atlas 2021. The prevalence rate of diabetes in Brazil is 13.4%, which is relatively high compared to other countries. Additionally, there is a significant proportion of undiagnosed cases, with a prevalence rate of 3.8%. The number of deaths attributable to diabetes in Brazil is estimated to be 144,600 in 2021, highlighting the seriousness of the disease in the country. The estimated healthcare expenditure related to diabetes in Brazil for 2021 is USD 26.8 billion. While the Diabetes Atlas does not provide specific data on annual incidence rates for Brazil, the high prevalence of diabetes suggests that there is also a significant incidence rate. This may be influenced by various factors, including age, genetics, lifestyle, and environmental factors. Overall, the high prevalence of diabetes in Brazil is a significant public health issue, with substantial societal and economic implications.

The high prevalence of diabetes in Brazil has a significant impact on the diabetes drugs market in the country. The increasing prevalence of diabetes in Brazil is one of the key drivers of this growth. As the number of people with diabetes continues to rise, there is a corresponding increase in demand for diabetes drugs. Additionally, Brazil's aging population and changing lifestyle habits, such as unhealthy diets and sedentary lifestyles, are contributing to the growing prevalence of diabetes in the country. To meet this growing demand, pharmaceutical companies are investing in research and development of new diabetes drugs and expanding their product portfolios. Insulin and oral hypoglycemic agents are among the most commonly used diabetes drugs in Brazil. The introduction of new drugs, such as SGLT2 inhibitors and GLP-1 agonists, is expected to further drive market growth.

brazil diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

The Brazil diabetes drugs market is driven by several factors, including the high prevalence of diabetes in the country, a growing aging population, and increasing demand for effective treatment options. One of the main drivers of the Brazil diabetes drugs market is the high prevalence of diabetes in the country. According to the International Diabetes Federation, Brazil has one of the largest diabetes populations in the world, with approximately 16.8 million adults living with the disease. This has led to significant demand for diabetes drugs in the country, as patients seek effective treatments to manage their condition.

Furthermore, the growing aging population. As the population ages, the incidence of diabetes is expected to increase, creating a greater demand for diabetes drugs. This is particularly relevant in Brazil, which has one of the fastest-growing aging populations in the world. As a result, there is an increasing need for innovative and effective diabetes drugs to meet the growing demand.

Market Restraints

One of the main challenges is the high cost of diabetes drugs, which can be a significant barrier to access for many patients. While the government provides universal healthcare coverage through the Unified Health System (Sistema Único de Saúde or SUS), the reimbursement rates for diabetes drugs may not always cover the full cost of treatment, leaving some patients without access to essential medications.

Moreover, the increasing use of generic drugs. Brazil has implemented policies to encourage the use of generic drugs, which are often more affordable than brand-name medications. While this has helped to reduce healthcare costs, it can also impact the growth of the diabetes drugs market by limiting the revenue potential for brand-name drugs.

Competitive Landscape

Key Players

Ache Laboratorios Farmaceuticos (BRA)
Biolab Sanus Farmaceutica (BRA)
Cristália Produtos Químicos (BRA)
EMS Sigma Pharma (BRA)
Boehringer Ingelheim
Sanofi
Boehringer Ingelheim
Eli Lilly and Company
AstraZeneca
Johnson & Johnson
Bayer Pharmaceuticals
Novo Nordisk
Merck
Novartis
GlaxoSmithKline

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The regulation of pharmaceutical products in Brazil is overseen by the National Health Surveillance Agency (ANVISA). ANVISA is responsible for evaluating the safety, efficacy, and quality of pharmaceutical products, including diabetes drugs, before they can be approved for sale in the Brazilian market. To be approved for sale in Brazil, diabetes drugs must undergo a rigorous evaluation process, including preclinical and clinical trials. ANVISA reviews data on the drug's safety and efficacy, as well as its manufacturing processes and quality control systems, to ensure that it meets the necessary standards for approval. Once a diabetes drug is approved by ANVISA, it must be registered with the Brazilian Ministry of Health before it can be sold in the country. The Ministry of Health is responsible for setting the reimbursement rates for pharmaceutical products in Brazil, including diabetes drugs.

In Brazil, the government provides universal healthcare coverage through the Unified Health System (Sistema Único de Saúde or SUS). Under the SUS, all Brazilian citizens have access to a range of healthcare services, including medications, at no cost. The Brazilian government negotiates prices for pharmaceutical products, including diabetes drugs, with manufacturers and sets a reimbursement rate for each product. The reimbursement rate is based on the negotiated price and the therapeutic value of the drug. In addition to the SUS, there are also private health insurance plans available in Brazil that may cover the cost of diabetes drugs. The coverage and reimbursement rates for diabetes drugs may vary depending on the specific insurance plan and the drugs prescribed.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.